Israel-based pharmaceutical firm Teva Pharmaceutical will acquire the remaining 50% stake of its Teva-Kowa Pharma joint venture, turning the venture into a wholly owned subsidiary.

Teva originally started the joint venture with Japanese firm Kowa in 2008 and will purchase the remaining stake for approximately $150m.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The move comes after generic manufacturer converted Taiyo Pharmaceuticals into a 100% subsidiary in July 2011 and will make Teva Japan’s largest generic drug company.

As a result of the acquisition, Teva has brought forward its 2015 sales target of 100bn yen ($1.3bn).

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now